The global bioprocess bags market size was valued at USD 2.81 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 17.14% from 2023 to 2030. The market is being driven by several factors such as the growing demand for biopharmaceuticals, including monoclonal antibodies and vaccines, advancements in bioprocess technology, such as single-use systems and disposable bioprocess bags, and the increasing adoption of modular manufacturing. Furthermore, the rising demand for personalized medicine is leading to the development of new biologics and other complex therapeutics, which require specialized manufacturing processes that can benefit from bioprocess bags. The COVID-19 pandemic has had a significant impact on the bioprocess bags market. The market is primarily driven by the biopharmaceutical industry, which has seen increased demand due to the development of COVID-19 vaccines and other advanced therapies.
The production of vaccines and protein therapeutics requires bioprocess bags for the production, storage, and transport of biologics. Furthermore, the pandemic has also resulted in a shift in focus toward single-use bioprocess bags. These are preferred over traditional stainless-steel tanks due to their low risk of contamination, increased flexibility, cost-effectiveness, and ease of use.
In February 2022, Dow; Südpack Medica; and Sartorius joined forces to produce bioprocessing bags that were crucial for manufacturing and transporting vaccines in the global fight against COVID-19. The collaboration involved the production of sterile bioreactor bags made from multi-layered films that can potentially hold a volume of approximately 2,000 liters. These bags are designed for optimized stirring and high oxygen transfer, making them suitable for mammalian cell culture processes that are microcarrier-based, or require high cell density.
These bags are made up of flexible plastic materials and are designed to withstand the rigorous demands of the biopharmaceutical manufacturing process. They are available in different sizes and varieties, depending on the specific requirements of manufacturers. The market is expected to register significant growth due to the rising demand for biopharmaceuticals. The demand for biopharmaceuticals is increasing due to several factors, including an aging population, the prevalence of chronic diseases, and the growing demand for personalized medicine. For instance, in 2022, approximately 340 biologics were approved by the Food and Drug Administration. As a result, the bioprocess bags industry is expected to grow significantly over the coming years.
Furthermore, the rising outsourcing activity by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) is expected to drive the demand for bioprocess bags. CMOs and CROs provide manufacturing and research services to pharmaceutical and biotech companies. The biopharma giants are increasingly outsourcing their bioprocessing activities, including the production, storage, and transportation of biologics, to third-party service providers.
Bioprocessing bags are essential for biologics manufacturing, and their demand is expected to grow as more companies outsource their bioprocessing activities. For instance, in July 2021, Pall Corporation announced a contract with Exothera S.A., valued at approximately $7 million. This new agreement is intended to create a suspension-based manufacturing platform capable of producing up to 2000L of product. The platform will utilize a range of technologies including Allegro STR single-use bioreactors to produce various viral vectors used in gene therapies and viral vector-based vaccines.
The 2D bioprocess bag segment held the highest market share of over 55% in 2022. This is due to the increasing demand for biopharmaceuticals and cell therapies. As the prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders continues to rise, the need for innovative and effective treatments continues to rise. Biopharmaceuticals offer a promising solution, and the use of 2D bioprocess bags can help streamline the manufacturing process and reduce costs.
The 2D bioprocess bags segment is also driven by technological advancements in bag design and materials. Manufacturers are developing bags with improved strength, durability, and resistance to punctures and leaks. Additionally, there is a growing trend toward customization and scalability, with bags designed to meet the specific requirements of different bioprocessing applications.
The 3D bioprocess bags segment is anticipated to grow at the fastest CAGR of 18.66% during the forecast period. They are commonly used in the production and storage of biologics, such as monoclonal antibodies, vaccines, and cell-based therapies. They provide a closed and sterile environment for cell culture, reducing the risk of contamination and ensuring the quality and consistency of the end product.
The growing demand for regenerative medicine and increasing government funding for regenerative medicine is driving the growth of the industry. For instance, in 2021, The Regenerative Medicine Innovation Project (RMIP) was introduced in collaboration between the US National Institutes of Health (NIH) and the Food and Drug Administration (FDA). The program supports the development of safe and effective regenerative medicine products. It also guides various industry stakeholders with information on best practices and the development of new tools and standards for evaluating regenerative medicine products. The program also encourages robust product development to ensure patient safety.
The upstream process segment held the highest market share of 43.45% in 2022. Bioprocessing bags are widely used in upstream processes for cell culture, media preparation, and fermentation. These bags provide a sterile and controlled environment for cell growth. Furthermore, these are designed to optimize cell growth and productivity. They are available in various sizes and offer varying attributes, making way for much-needed flexibility and scalability in upstream processes. The demand for bioprocessing bags in upstream processes is driven by several factors, including the growing demand for biopharmaceuticals and vaccines, the shift toward single-use technologies, and the benefits of using disposable bags in terms of cost, efficiency, and risk reduction.
The downstream process segment is anticipated to register the fastest CAGR of 17.67% during the forecast period. Bioprocess bags are widely used in the downstream process for storing and transporting the product during various stages of purification. They offer several advantages over traditional stainless steel vessels, including a lower risk of contamination, reduced cleaning and validation requirements, and faster turnaround times. For instance, Sartorius AG offers flexsafe bags, which are made from high-quality materials and are available in various sizes, ranging from 50 mL to 1,000 L. The bags are designed to be used with Sartorius' flexboy and flexboy Advance disposable bioreactors, providing a complete single-use solution for downstream bioprocessing.
The pharmaceutical & biopharmaceutical companies segment held the highest market share of 46.18% in 2022. The strategic initiatives undertaken by key market players such as expansion, new product launch, merger & acquisition, and collaboration offer lucrative opportunities. For instance, in February 2021, Saint-Gobain announced the launch of highly efficient cell culture bags for T-cell expansion. These new cell culture bags are designed to provide a sterile and controlled environment for the growth and expansion of T-cells, which are an essential component of the immune system and are used in cell-based therapies for the treatment of various diseases.
The CMOs & CROs segment is anticipated to register the fastest CAGR of 18.16% over the forecast period. The adoption of contract services is being fueled by several benefits offered by CROs and CMOs, including scalability, flexibility, reduced internal infrastructure requirements, and dedicated supply channels. As a result, these advantages are expected to have a positive impact on the growth of the industry in the near future. Also, the outsourcing of bioprocessing activities allows companies to focus on their core competencies, reduce costs, and improve efficiency. This trend has led to an increase in the number of CMOs and CROs, which, in turn, is expected to drive the growth of the market.
North America region dominated the global market with a share of 35.27% in 2022. The increasing demand for biopharmaceuticals is expected to drive the growth of the bioprocess bags market in the region. Other factors that are expected to contribute to the growth include the increasing adoption of single-use bioprocessing technologies and the growing focus on reducing the high costs associated with the bioprocessing of advanced therapies. Additionally, the presence of major biopharmaceutical companies and contract manufacturing organizations (CMOs) in North America is expected to drive the growth of the market in the region. These companies require high-quality bioprocess bags for their operations.
The Asia Pacific is estimated to become the fastest-growing region with a CAGR of 20.04% during the forecast period. The growing population, with increasing healthcare needs is expected to remain the key contributor to growth. Another factor driving the growth of the bioprocess bags industry in the Asia Pacific region is the increasing investment in the biopharmaceutical industry. Governments and private investors in countries like China, Japan, and South Korea are investing heavily in the biopharmaceutical industry, which is expected to drive the demand for bioprocess bags.
The market for bioprocess Bags is highly competitive with the presence of well-established as well as small and mid-sized emerging players. A prominent number of players are rapidly opting for geographical expansion, strategic collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions.
For instance, in April 2022, Thermo Fischer Scientific, Inc. announced the opening of a new manufacturing facility in Ogden, Utah, that will manufacture materials and technology needed for the development of new vaccines and therapies. The facility is part of Thermo Fisher's investment of USD 650 million to ensure a reliable bioprocessing production capacity for crucial materials used in creating biologics and vaccines, including COVID-19 vaccines. This investment will enable the company to meet the increasing demand for single-use technology and contribute to the development of innovative therapies and vaccines. The facility is valued at approximately USD 44 million. Some prominent players in the global bioprocess bags market include:
Thermo Fisher Scientific Inc.
Meissner Filtration Products, Inc.
CellBios Healthcare And Lifesciences Pvt Ltd.
Market size value in 2023
USD 3.37 billion
Revenue forecast in 2030
USD 10.21 billion
CAGR of 17.14% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million, CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, workflow, end-user, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand;South Korea; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Thermo Fisher Scientific Inc.; Sartorius AG; Danaher Corporation; Merck KGaA; Saint-Gobain; Corning Incorporated; Entegris, Meissner Filtration Products, Inc.; PROAnalytics, LLC; CellBios Healthcare And Lifesciences Pvt Ltd.
Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global bioprocess bags market report based on type, workflow, end-user, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
2D Bioprocess Bags
3D Bioprocess Bags
Other Bags & Accessories
Workflow Outlook (Revenue, USD Million, 2018 - 2030)
End-User Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biopharmaceutical Companies
CMOs & CROs
Academic & Research Institutes
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa (MEA)
b. The global bioprocess bags market size was estimated at USD 2.81 billion in 2022 and is expected to reach USD 3.37 billion in 2023.
b. The global bioprocess bags market is expected to grow at a compound annual growth rate of 17.14% from 2023 to 2030 to reach USD 10.21 billion by 2030.
b. The upstream process segment held the largest share of 43.45% in 2022. Bioprocessing bags are widely used in upstream processes for cell culture, media preparation, and fermentation.
b. Some key players operating in the bioprocess bags market include Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation, Merck KGaA, Saint-Gobain, Corning Incorporated, Entegris, Meissner Filtration Products, Inc., PROAnalytics, LLC, CellBios Healthcare And Lifesciences Pvt Ltd.
b. The market is being driven by several factors such as, the growing demand for biopharmaceuticals, including monoclonal antibodies and vaccines, advancements in bioprocess technology, such as single-use systems and disposable bioprocess bags, and the increasing adoption of modular manufacturing.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."